LivaNova (LIVN)
(Delayed Data from NSDQ)
$53.22 USD
+0.03 (0.06%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $53.30 +0.08 (0.15%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$53.22 USD
+0.03 (0.06%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $53.30 +0.08 (0.15%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum D VGM
Zacks News
LivaNova's (LIVN) Study to Evaluate VNS Therapy Gets CMS Nod
by Zacks Equity Research
LivaNova (LIVN) is aiming to reach out to more patients, with improved enrollment program.
LivaNova (LIVN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 2.94% and 1.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More
by Zacks Equity Research
Solid growth in emerging markets is expected to be an added positive this earnings season.
Analysts Estimate LivaNova (LIVN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova (LIVN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova (LIVN) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of -10.34% and -0.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stock Q3 Earnings on Oct 31: BAX, MASI & More
by Zacks Equity Research
Long-term growth prospects of the Medical Products industry looks promising despite certain short-term political conundrums.
LivaNova (LIVN) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova (LIVN) Soars: Stock Adds 10.4% in Session
by Zacks Equity Research
LivaNova (LIVN) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
LivaNova (LIVN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 5.49% and 3.48%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
MedTech's Long-Term Prospects Outweigh Near-Term Risks
by Mark Vickery
A growing prevalence of minimally invasive surgeries, rising demand for liquid biopsy tests, use of IT for ensuring quick and improved patient care and the shift of the payment system to a value-based model are among the updates.
4 Growth Stocks to Pick From a Choppy MedTech Market
by Zacks Equity Research
In the wake of the volatile political scenario and taking a few favorable metrics into account, these MedTech stocks stand out as the most suitable picks.
4 Top Growth Picks to Avoid Tax Tangle in MedTech
by Zacks Equity Research
Despite the ongoing tax bill-related disputes in the MedTech industry, these stocks with high growth potential can be great bets for investors.
The Power of New Analyst Coverage
by Kevin Matras
Kevin Matras shows why stocks with new analyst coverage are stocks you want to have. Highlighted stocks include LIVN, CLDT, ASML, HEI and ETSY.
Cross Country and Cyberonics, Two Strong Buys
by Brian Bolan
These two names might not be on your radar list, but they should be!